HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together ...

positive unrespectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)." FDA has not approved Sun Pharma's Imatinib Mesylate Tablet products for this indication.

MUMBAI, India & CRANBURY, N.J.--(BUSINESS WIRE)--As part of the company’s philosophy of putting patients' interests first, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE ...

This is because the 400-mg tablets contain more of the drug’s active ingredient (imatinib mesylate). They’re also packaged differently. The 400-mg tablets come in blister packs and the 100-mg ...

It comes as an oral tablet. Gleevec is available as a generic drug called imatinib mesylate. For information about the dosage of Gleevec, including its strengths and how to take the drug ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

The Food and Drug Administration has cleared Zydus Cadila’s imatinib mesylate tablets, in dosage strengths of 100 mg and 400 mg. The product is the generic of Novartis’ Gleevec tablets.

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec Tablets in the U.S. market approved by ...

As a result, FDA has not approved Sun Pharma's Imatinib Mesylate Tablet products for this indication. For safety information please refer to U.S. Full Prescribing Information at www.imatinibrx.com ...